Laszlo D, Bosi A, Guidi S, Saccardi R, Vannucchi A M, Lombardini L, Longo G, Fanci R, Azzi A, De Santis R
Bone Marrow Transplant Unit, University of Florence, Azienda Ospedaliera di Careggi, Italy.
Haematologica. 1995 Sep-Oct;80(5):421-5.
Hemorrhagic cystitis (HC) is a major complication of high-dose cyclophosphamide therapy used in the preparative regimen for allogeneic or autologous bone marrow transplantation. Several viruses (adenovirus, cytomegalovirus and polyomavirus BK) have also been implicated in the etiology of HC. No one established method of treatment is as yet available.
HC developed in 10 patients after allogeneic bone marrow transplantation and was BK viruria-associated in all cases. All patients were treated with instillations of prostaglandin E2 (PGE2) directly into the bladder.
A complete resolution of hematuria within a short time (5 +/- 1 days) was observed in all cases; in 4/10 patients urine cleared within 24 hours of the initial treatment. Intravesical PGE2 therapy caused no systemic circulatory or respiratory problems, although bladder spasms occurred in all patients.
Intravesical prostaglandin E2 instillation appears to be an effective treatment for hemorrhagic cystitis in bone marrow transplant patients; further studies are required to assess the actual role of BK virus in the pathogenesis of HC in bone marrow transplant patients.
出血性膀胱炎(HC)是同种异体或自体骨髓移植预处理方案中使用高剂量环磷酰胺治疗的主要并发症。几种病毒(腺病毒、巨细胞病毒和多瘤病毒BK)也与HC的病因有关。目前尚无一种既定的治疗方法。
10例同种异体骨髓移植后发生HC,所有病例均与BK病毒尿有关。所有患者均接受直接向膀胱内灌注前列腺素E2(PGE2)治疗。
所有病例均在短时间内(5±1天)血尿完全消退;4/10患者在初始治疗后24小时内尿液清澈。膀胱内灌注PGE2治疗未引起全身循环或呼吸问题,尽管所有患者均出现膀胱痉挛。
膀胱内灌注前列腺素E2似乎是治疗骨髓移植患者出血性膀胱炎的有效方法;需要进一步研究以评估BK病毒在骨髓移植患者HC发病机制中的实际作用。